{
    "2019-04-07": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Why Amgen's Giving Novartis a Headache",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Novartis",
                        "Headache"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Should Biogen Investors Be Extra Nervous Right Now?",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Investors",
                        "Nervous"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}